News

New indication: FDA approved Zolpidem tartrate sublingual tablets or the treatment of insomnia characterized by middle-of-the-night (MOTN) wakening followed by difficulty returning to sleep.

Orally inhaled dihydroergotamine (DHE) is a newly developed formulation of DHE for the treatment of acute migraine attack and is undergoing FDA review.

Hospital-acquired Clostridium difficile significantly prolongs the duration of a patient's stay in the hospital by at least 6 days, according to the findings of a study published online December 5, for the Canadian Medical Association Journal.

Methotrexate alone, with step up to other therapies only if a response is not achieved, is a reasonable starting strategy for treating "poor prognosis" rheumatoid arthritis (RA), said James O'Dell, MD, at the annual scientific meeting of the American College of Rheumatology, Chicago.

Romiplostim (Nplate, Amgen), a synthetic protein that binds to and stimulates the thrombopoietin receptor, induced a rapid platelet response in most adult patients with immune thrombocytopenia (ITP) who had low platelet counts or bleeding symptoms, regardless of splenectomy status.

Recent FDA action (through January 2012) related to dapagliflozin, progesterone vaginal gel 8%, ACH-1625 protease inhibitor, CPP-115 GABA aminotransferase inhibitor, AC607, NBI-98854 VMAT2 inhibitor, AIC246 inhibitor, CBP501, Porfimer sodium, inhaled nitric oxide, carbamazepine extended-release capsules, levetiracetam extended-release tablets

In mid-December, FDA reported that dronedarone (Multaq) increased the risk of serious cardiovascular events, including death, when used in patients with permanent atrial fibrillation (AF), according to its safety drug communication.

The healthcare overhaul has allowed 2.5 million young adults to gain insurance coverage under their parents' plans, a figure that is more than double previous estimates.

Savings of $4.5 billion over 10 years is the projection by the federal governement relative to a new rule to standardize electronic funds transfers.

When it comes to health insurance and the Patient Protection and Affordable Care Act, defintion "affordable" can be a complex and confounding task.

Supreme Court unlikely to allow live C-SPAN coverage of the five and half hour healthcare reform hearing, unfortunately.

Health Care Service Corporation offers defined-contribution plans in a private-exchange model.

In administrating Commonwealth Care, the Massachusetts' Connector has been hugely successful in enrolling people in subsidized health plans. As of last August, nearly 40,000 people had used the Connector to purchase Commonwealth plans.

Economists reported an "extraordinary" slow down in healthcare spending for 2010, largely because of the recession and unemployment.

Consider hybrid alternatives when switching to cloud computing.

According to experts, improving accessibility to laboratory tests and results improves patient engagement in their health and could have significant cost saving implications for managed care.

Programs need to not only prevent infections but also eliminate them.

GOP candidate Mitt Romney argues that his proposal to convert Medicare from a defined-benefit program to a defined-contribution program will rescue Medicare by creating competition among plans and drive down costs. Republican Paul Ryan and Democratic Senator Ron Wyden have a similar proposal.

FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days.

FDA recently announced that a clinical trial evaluating the effects of doripenem (Doribax, Janssen) on the treatment of patients with ventilator-associated pneumonia was halted because of an increase in death rate and a poor clinical cure rate.

FDA and Seattle Genetics, which makes brentuximab vedotin (Adcetris), have updated the warning label on the company’s cancer drug after a second patient developed progressive multifocal leukoencephalopathy.

Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine.

Older women who use statins may be at an increased risk for diabetes mellitus, according to the results of a study published online January 9, in the Archives of Internal Medicine.

Approximately 1 in 100 patients undergoing total or partial knee replacement surgery and 1 in 200 patients undergoing total or partial hip replacement surgery will experience a venous thromboembolism event, including deep vein thrombosis and pulmonary embolism, before being discharged from the hospital, according to a new study.

The Endocrine Society recently released new clinical practice guidelines recommending that all patients have their blood-glucose levels tested upon admission to the hospital, even if they haven’t been diagnosed with diabetes.

Indian drug giant Ranbaxy has accepted a consent decree filed by the U.S. Department of Justice on behalf of FDA. The decree, which must still be accepted by the U.S. District Court for the District of Maryland, requires Ranbaxy to fix long-standing manufacturing problems at plants in India as well as a plant in the United States.

Health Choice Arizona has instituted a new scheduling system to help it connect patients with appropriate community health resources on a timely basis. It wanted to find a way to help those members with the lowest incidence of preventive service completion quickly schedule their appointments.

One of the largest pharmacy benefits managers in the U.S. is about to get bigger. Health Net Inc. says it will sell its Medicare prescription-drug plan (PDP) business to CVS Caremark Corp. (CVS) for about $160 million in cash.

Managing consulting firm Peppers & Rogers Group released the results of its Trustability in Health Care study, which showed that consumers are willing to pay more for services from trustworthy health insurers. Respondents said they would be willing to pay on average $30 a month more to do business with a health insurer they trust, with some willing to pay up to $100 a month total

A slowing of the growth in use of healthcare goods and services contributed to a second year of slow health spending growth in 2010, according to federal analysts. A number of factors combined to make 2009 and 2010 the two slowest growth rates in 51-year history of National Health Expenditure Accounts estimates.